Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Up 64.7% in April

Xenetic Biosciences Inc (NASDAQ:XBIO) was the recipient of a significant growth in short interest in April. As of April 15th, there was short interest totalling 2,800 shares, a growth of 64.7% from the March 31st total of 1,700 shares. Based on an average trading volume of 5,800 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.2% of the shares of the stock are short sold.

Xenetic Biosciences Stock Performance

XBIO stock opened at $4.09 on Friday. The company has a market capitalization of $6.30 million, a PE ratio of -1.49 and a beta of 2.60. Xenetic Biosciences has a one year low of $2.55 and a one year high of $5.97. The company’s 50 day moving average price is $4.09 and its two-hundred day moving average price is $3.72.

Xenetic Biosciences (NASDAQ:XBIO) last announced its quarterly earnings results on Thursday, March 21st. The company reported ($0.77) EPS for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.10. The business had revenue of $0.67 million for the quarter, compared to analysts’ expectations of $0.68 million. Xenetic Biosciences had a negative return on equity of 36.43% and a negative net margin of 162.84%. On average, research analysts predict that Xenetic Biosciences will post -3.43 EPS for the current year.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.